Drug class
Peptide-conjugated alkylating antineoplastic agent; melphalan prodrug-like peptide conjugate
Mechanism of action
Melphalan flufenamide is a peptide-conjugated alkylating agent designed to be taken up by cells and cleaved by intracellular peptidases to release melphalan. Melphalan alkylates DNA, causing DNA crosslinking and inhibition of DNA synthesis and tumour-cell proliferation.
General use cases
- Historical US indication: in combination with dexamethasone for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy and refractory to specified prior agents. US approval was withdrawn effective 23 February 2024; do not present it as a current US-authorised treatment.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
